COVID-19 trials registries data warehouse

https://jrct.niph.go.jp/latest-detail/jRCTs031190269

Terada Junko

jterada@hosp.ncgm.go.jp

2020-03-27

Not recruiting

RCT

Randomized

Parallel

Open label

multi-center

Treatment

1) Patient who have given written consent to participate in the study2) Age is over 20 years old, regardless of gender.3) SARS-CoV-2 PCR positive4) Patients who have no apparent pneumonia due to COVID-19 on plain chest radiographs5) Patients who can be hospitalized during study drug administration (Including accommodation and medical treatment)6) Patients who can inhale ciclesonide using inhalation assist device

1) Patients with a history of hypersensitivity to Ciclesonide2) Except for COVID-19, who have infectious disease or deep mycosis without an effective antibacterial agent3) Patients using inhaled or oral steroids4) Patients with fever of 37.5 degrees for 7 days 5) Patients co-administering treatments that may have therapeutic effects on COVID-196) Patients who are considered inappropriate for inclusion in the study by the investigator

2

Sugiyama Haruhito

20

None

Japan

Mild disease at enrollment

1: Mild disease at enrollment

90

Pneumonia incidence on day 8 of ciclesonide inhalation

Phase 2

[{"arm_notes": "", "treatment_id": 282, "treatment_name": "Ciclesonide", "treatment_type": "Corticosteroids", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]